{"title":"阿立哌唑治疗自闭症谱系障碍(ASD)， Cochrane综述","authors":"Lauren Hirsch, T. Pringsheim","doi":"10.1192/bja.2023.15","DOIUrl":null,"url":null,"abstract":"Autism spectrum disorders (ASD) include autistic disorder, Asperger’s disorder and pervasive developmental disorder not otherwise specified (PDD-NOS). Antipsychotics have been used as a medication intervention for irritability related to ASD. Aripiprazole, a third-generation, atypical antipsychotic, is a relatively new drug that has a unique mechanism of action different from that of other antipsychotics. This review updates a previous Cochrane review on the safety and efficacy of aripiprazole for individuals with ASD, published in 2011 (Ching 2011).","PeriodicalId":9336,"journal":{"name":"BJPsych Advances","volume":"17 1","pages":"289 - 289"},"PeriodicalIF":1.7000,"publicationDate":"2023-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Aripiprazole for autism spectrum disorders (ASD), a Cochrane Review\",\"authors\":\"Lauren Hirsch, T. Pringsheim\",\"doi\":\"10.1192/bja.2023.15\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Autism spectrum disorders (ASD) include autistic disorder, Asperger’s disorder and pervasive developmental disorder not otherwise specified (PDD-NOS). Antipsychotics have been used as a medication intervention for irritability related to ASD. Aripiprazole, a third-generation, atypical antipsychotic, is a relatively new drug that has a unique mechanism of action different from that of other antipsychotics. This review updates a previous Cochrane review on the safety and efficacy of aripiprazole for individuals with ASD, published in 2011 (Ching 2011).\",\"PeriodicalId\":9336,\"journal\":{\"name\":\"BJPsych Advances\",\"volume\":\"17 1\",\"pages\":\"289 - 289\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2023-04-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BJPsych Advances\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1192/bja.2023.15\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BJPsych Advances","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1192/bja.2023.15","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PSYCHIATRY","Score":null,"Total":0}
Aripiprazole for autism spectrum disorders (ASD), a Cochrane Review
Autism spectrum disorders (ASD) include autistic disorder, Asperger’s disorder and pervasive developmental disorder not otherwise specified (PDD-NOS). Antipsychotics have been used as a medication intervention for irritability related to ASD. Aripiprazole, a third-generation, atypical antipsychotic, is a relatively new drug that has a unique mechanism of action different from that of other antipsychotics. This review updates a previous Cochrane review on the safety and efficacy of aripiprazole for individuals with ASD, published in 2011 (Ching 2011).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
